cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Coherus Biosciences Inc
16 own
11 watching
Current Price
$1.61
$0.18
(12.59%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
433.83M
52-Week High
52-Week High
5.46500
52-Week Low
52-Week Low
1.25000
Average Volume
Average Volume
1.58M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
9.1545
iconMarket Capitalization433.83M
icon52-Week High5.46500
icon52-Week Low1.25000
iconAverage Volume1.58M
iconDividend Yield--
iconP/E Ratio9.1545
What does the Coherus Biosciences Inc do?
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, nonsmall cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behcet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Read More
How much money does Coherus Biosciences Inc make?
News & Events about Coherus Biosciences Inc.
Globe Newswire
1 year ago
YUSIMRY (adalimumab-aqvh) product image YUSIMRY (adalimumab-aqvh) - list price $995 per carton of two 40 mg/0.8 mL autoinjectorsSee https://www.yusimry.com for YUSIMRY Full Prescribing Information, including Boxed Warning and Medication guide. $995 per carton (two 40 mg/0.8 mL autoinjectors) ...
Globe Newswire
1 year ago
REDWOOD CITY, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today announced that effective June 20, 2023, the compensation committee of the Companys board of directors granted options to purchase an aggregate of 48,000 shares of the ...
Globe Newswire
1 year ago
Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues Acquisition significantly advances Coherus I-O pipeline with anti-IL-27 and anti-CCR8 clinical programs ...
Globe Newswire
1 year ago
Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues Acquisition significantly advances Coherus I-O pipeline with anti-IL-27 and anti-CCR8 clinical programs ...
Globe Newswire
1 year ago
- UDENYCA is the only pegfilgrastim therapy delivered in a convenient, easy-to-administer prefilled autoinjector to offer in-clinic and at-home administration options for cancer patients undergoing myelosuppressive chemotherapy - - An additional presentation, the UDENYCA proprietary on-body injector...
Frequently Asked Questions
Frequently Asked Questions
What is Coherus Biosciences Inc share price today?
plus_minus_icon
Can Indians buy Coherus Biosciences Inc shares?
plus_minus_icon
How can I buy Coherus Biosciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Coherus Biosciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Coherus Biosciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Coherus Biosciences Inc?
plus_minus_icon
What is today’s market capitalisation of Coherus Biosciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Coherus Biosciences Inc?
plus_minus_icon
What percentage is Coherus Biosciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Coherus Biosciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.61
$0.18
(12.59%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00